A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

ABSTRACT:

Background

A key missing element in the development of a successful human immunodeficiency virus (HIV) vaccine is an immunogen that can generate broadly cross-neutralizing antibodies against primary isolates of the virus.

Methods

This phase 1 clinical trial employed a DNA prime and subunit envelope protein boost in an attempt to generate cellular and humoral immune responses that might be desirable in a protective HIV vaccine. Priming was performed via intramuscular injection with gag and env DNA adsorbed to polylactide coglycolide microspheres, followed by boosting with a recombinant trimeric envelope (Env) glycoprotein delivered in MF59 adjuvant.

Results

The DNA prime and protein boost were generally safe and well-tolerated. Env-specific CD4(+) cellular responses we

SUBMITTER: Spearman P 

PROVIDER: S-EPMC3068023 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature